Previous Article | Next Article ![]()
Journal of Virology, December 2001, p. 11408-11416, Vol. 75, No. 23
Department of
Immunology1 and Divisions of
Infectious Diseases2 and Experimental
Pathology,3 Mayo Clinic, Rochester,
Minnesota 55905
Received 29 January 2001/Accepted 3 August 2001
The role of NF-
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.23.11408-11416.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
NF-
B cis-Acting Motifs of the Human
Immunodeficiency Virus (HIV) Long Terminal Repeat Regulate HIV
Transcription in Human Macrophages
B in the reactivation of human immunodeficiency
virus (HIV) from latency in CD4 T lymphocytes is well documented. However, its role in driving HIV transcription in human macrophages, which contain a constitutive nuclear pool of NF-
B, is less well understood. In this study we have investigated the role that the constitutive pool of NF-
B and the NF-
B cis-acting
motifs of the HIV long terminal repeat (LTR) play in regulating HIV
transcription in human monocytic cells and primary macrophages.
Inhibition of the constitutive nuclear pool of NF-
B (RelA and RelB)
in the promonocytic U937 cell line using dominant-negative I
B
significantly decreases HIV replication. Moreover, it is demonstrated
that in the differentiated monocytic cell line THP1, which contains a constitutive nuclear pool of NF-
B (RelB),an HIV provirus containing mutations of the
B cis-acting sites in the LTR is
transcriptionally impaired. Reduction of the constitutive pool of
NF-
B in human macrophages by an adenovirus vector expressing a
dominant-negative I
B
also reduces HIV transcription. Lastly,
mutation of the NF-
B cis-acting sites in the LTR of
an R5 HIV provirus completely abrogates the first cycle of HIV
transcription. These studies indicate that the
cis-acting NF-
B motifs of the HIV LTR are critical in
initiating HIV transcription in human macrophages and suggest that the
constitutive nuclear pool of NF-
B is important in regulating HIV
transcription in these cells.
*
Corresponding author. Mailing address: Mayo Clinic, 200 First St., SW, Guggenheim 501, Rochester, MN 55905. Phone: (507)
284-3747. Fax: (507) 284-3757. E-mail: paya{at}mayo.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»